84
Participants
Start Date
March 10, 2020
Primary Completion Date
October 21, 2024
Study Completion Date
October 21, 2024
Infigratinib 0.016 mg/kg
"Initial cohort dose of infigratinib at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth."
Infigratinib 0.032 mg/kg
"Subsequent cohort dose escalation based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth."
Infigratinib 0.064 mg/kg
"Subsequent cohort dose escalation based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth."
Infigratinib 0.128 mg/kg
"Subsequent cohort dose escalation based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth."
Infigratinib 0.25 mg/kg
"Subsequent cohort dose escalation based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth."
Murdoch Children's Hospital, Parkville
Nemours Alfred I. Dupont Hospital for Children, Wilmington
Johns Hopkins School of Medicine, Baltimore
Hospital Universitario La Paz, Madrid
Vanderbilt University Medical Center, Nashville
Cincinnati Children's Hospital Medical Center, Cincinnati
UCSF Benioff Children's Hospital, Oakland
Stollery Children's Hospital, Edmonton
Hopital Femme Mere Enfant, Lyon
Hopital Necker-Enfants Malades, Paris
Hopital des Enfants, Toulouse
Hospital Universitario Virgen de la Victoria, Málaga
Birmingham Children's Hospital, Birmingham
Queen Elizabeth University Hospital, Glasgow
Evelina London Children's Hospital, London
Manchester University Children's Hospital, Manchester
Vithas Hospital San José, Vitoria-Gasteiz
Sheffield Children's Hospital, Sheffield
University Hospitals Bristol and Weston NHS Foundation Trust, Bristol
QED Therapeutics, Inc., a Bridgebio company
INDUSTRY